louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02032953: Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
Official title: Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Colorectal Cancer
Keywords: colorectal cancer
protein recovery
perioperative nutrition
hyperinsulinemia
normoglycemia
hyperinsulinemic-normoglycemic clamp
anabolism
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2014-01-10
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists class\<3
* age\>18 years
* colorectal surgery for non-metastatic colorectal adenocarcinoma including right and left hemicolectomy, transverse, subtotal and total colectomy sigmoid and low anterior resection
* ability to give informed consent

Exclusion Criteria:

* BMI\>30 Kg/meter squared
* confirmed diagnosis of diabetes mellitus or a HbA1c\>6.0%
* significant cardiorespiratory, hepatic, renal and neurological disease
* musculoskeletal or neuromuscular disease
* ingestion of drugs known to affect protein, glucose and lipid metabolism (e.g. steroids)
* severe anemia (hemoglobin\<10 g/dL
* pregnancy
* history of severe sciatica, back surgery or other conditions which contraindicate the use of epidural catheters

Primary outcomes:
measure: Net protein balance
timeFrame: 6 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: McGill University Health Centre (MUHC) - Royal Victoria Hospital
state: Quebec
Study officials:
affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
name: Thomas Schricker, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schricker T, Meterissian S, Wykes L, Eberhart L, Lattermann R, Carli F. Postoperative protein sparing with epidural analgesia and hypocaloric dextrose. Ann Surg. 2004 Nov;240(5):916-21. doi: 10.1097/01.sla.0000143249.93856.66.
citation: Schricker T, Wykes L, Carli F. Epidural blockade improves substrate utilization after surgery. Am J Physiol Endocrinol Metab. 2000 Sep;279(3):E646-53. doi: 10.1152/ajpendo.2000.279.3.E646.
Clinical trial NCT02996253: Endoscopic Transfer of Flexor Hallucis Longus Tendon for Chronic Achilles Tendon Rupture
Official title: Endoscopic Assisted Transfer of Flexor Hallucis Longus Tendon for Chronic Achilles Tendon Rupture. A Prospective Multi Center Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Achilles Tendon Rupture
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: Central Hospital, Fredrikstad
First posted: 2016-12-19
Enrollment: 38
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients With chronic Achilles Tendon Rupture

Brief summary: The transfer of Flexor Hallucis Longus (FHL) in the management of chronic Achilles tendon ruptures has demonstrated good functional outcome, but an extensive surgical field at a vulnerable location may lead to increased risk for soft tissue problems. The arthroscopic FHL transfer may reduce the risk for soft tissue problems. Functional outcome parameters are investigated, wound/soft tissue complications registered.

Detailed description: The transfer of FHL in the management of chronic Achilles tendon ruptures has demonstrated good functional outcome with American Orthopaedic Foot ane Ankle Society (AOFAS) hindfoot scores at 80-89. The extensive surgical field by either a two-incision approach or a single longitudinal posterior approach to the Achilles tendon may lead to an increased risk for soft tissue problems, both infections and wound healing problems. The endoscopic FHL transfer may reduce the risk for soft tissue problems while retaining a good functional outcome. Several functional outcome measures and scores are evaluated a year after surgery.

Prospective study for evaluation of the surgical procedure.

Eligibility criteria: Inclusion Criteria:

* Chronic Achilles Tendon Rupture

Exclusion Criteria:

* Pregnancy
* BMI\<18.5 or \>39.9
* Insufficient Norwegian Language proficiency lack of communication skills local skin conditions at site for planned surgery

Primary outcomes:
measure: The Victorian Institute of Sports Assessment- Achilles Questionnaire (VISA-A) outcome score
timeFrame: one year after FHL transfer
Secondary outcomes:
measure: Visual Analogue Scale for Pain (VAS pain) score
timeFrame: 3, 6 and 12 months after FHL transfer
measure: patient reported function score (PRFS)
timeFrame: 6, 12 months
measure: Magnetic resonance imagine (MRI)
timeFrame: one year post surgery
measure: functional test battery
timeFrame: 12 months
measure: local wound conditions
timeFrame: within 12 weeks
measure: AOFAS hindfoot
timeFrame: 3,6,12 months
measure: VISA-A
timeFrame: 6 months after surgery
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Oslo University Hospital
name: Elisabeth E Husebye, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05134753: PRF Versus Advanced PRF in Sinus Augmentation
Official title: Platelet Rich Fibrin Versus Advanced Platelet Rich Fibrin as Bone Graft Material in Sinus Augmentation (Randomized Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Maxillary Sinus
Keywords: PRF
Advanced PRF
Sinus augmentation
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-11-26
Enrollment: 32
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In the present study the main hypothesis , Advanced PRF will improve the bone quality and quantity in sinus augmentation


Eligibility criteria: Inclusion Criteria:

* The Patients with missing posterior maxillary teeth with insufficient available bone for implant placement indicating the need for maxillary sinus floor augmentation before implantation.

  2. The Patients should be free from any systemic disease that may affect normal healing of bone, and predictable outcome.

  3. The Patients should be free from any sinus disease that might affect the health and integrity of the sinus lining.

  4. Assign an informed consent to be involved in the study.

Exclusion Criteria:

Patients with any systemic disease that may affect normal healing. 2. Patients with any sinus disease.

-

Primary outcomes:
measure: Bone quality
timeFrame: Six months
Secondary outcomes:
measure: Bone quantity
timeFrame: Six months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04900753: Risk Factors Related to Thirst After Surgery
Official title: Rrisk Factors of Xerostomia (Dry Mouth) After Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Complications
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2021-05-25
Enrollment: 472
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: over 19 years old elective surgery patients

Brief summary: To investigate the risk factors related to xerostomia (dry mouth) after surgery

Detailed description: Dry mouth of postoperative makes the patient feel thirst, and the pain of the lips is cracked. It will also make the sputum thick and sticky, making it difficult for the patient to cough by himself. Especially the elderly may have sputum accumulation and pneumonia. The incidence of dry mouth was 88%, 6-8 hours after abdominal surgery. Initiating the motivation of this study, it is hoped that through research to understand the relevant factors causing dry mouth after surgery.

Eligibility criteria: Inclusion Criteria:

1. Hospitalized patients
2. Elective surgery patients
3. \>19 years old patients

Exclusion Criteria:

1. cognitive impairment patients
2. ICU patients

Primary outcomes:
measure: To investigate the risk factors related to xerostomia (dry mouth) after surgery
timeFrame: 5 mins
Secondary outcomes:
Other outcomes:
Locations:
city: Taoyuan
country: Taiwan
facility: Hsiu-Ling Yang
state: No.5, Fuxing St., Guishan Dist
Study officials:
References:
Clinical trial NCT00978653: The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure
Official title: Prospective Study of Allopurinol Treatment That Improves Endothelial Function by Decreasing Uric Acid Levels of Patients With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperuricemia
Chronic Kidney Disease
Keywords: allopurinol
chronic kidney disease
endothelial dysfunction
hyperuricemia
uric acid
vascular endothelium
xanthine oxidase inhibitor
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2009-09-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients with chronic kidney disease.

Detailed description: Endothelial dysfunction (ED) is a key event in the development of atherosclerotic cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental models have shown that hyperuricemia causes hypertension and renin angiotensin system activation. In this prospective study, the investigators aimed to evaluate the effects of improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.

Eligibility criteria: Inclusion Criteria:

* Laboratory finding of hyperuricemia
* Patients between ages of 18 and 60 years
* Non-diabetic patients
* Creatinine clearance values between 20 and 60 mL/min/1.73 m2

Exclusion Criteria:

* Low (\< 20 ml/min/1.73 m2) creatinine clearance,
* Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
* Patients taking urate lowering medication (allopurinol and probenecid)

Primary outcomes:
measure: Endothelial function improvement with uric acid lowering treatment
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Faculty of Medicine
Study officials:
affiliation: Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
name: Berna Yelken, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
name: Yasar Caliskan
role: PRINCIPAL_INVESTIGATOR
affiliation: Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
name: Alaattin Yildiz, Prof, MD
role: STUDY_DIRECTOR
affiliation: Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
name: Numan Gorgulu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01684553: The Effect of Changing the Eating Speed on Energy Intake
Official title: The Effect of Changing the Eating Speed on Energy Intake: a Randomized Cross-over Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oral Intake Reduced
Keywords: Eating speed
energy intake
Lead sponsor: Texas Christian University
Sponsor class: OTHER
First posted: 2012-09-13
Enrollment: 70
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: It was hypothesized that eating a meal slowly would lead to a lower meal energy intake and lesser feelings of hunger and desire to eat and higher levels of fullness after the meal compared to eating the same meal more quickly.


Eligibility criteria: Inclusion Criteria:

* Men and women ages 19-65 years.

Exclusion Criteria:

* Severe obesity (BMI ≥ 40 kg/m2),
* dieting,
* taking medications that affect appetite,
* participating in \> 150 min/wk of vigorous physical activity,
* smoking,
* drinking heavily (men: \> 14 alcoholic drinks/wk; women: \> 7 alcoholic drinks/wk),
* self-reported disordered eating,
* depression,
* type 1 or 2 diabetes,
* adrenal disease, or
* untreated thyroid disease.

Primary outcomes:
measure: Meal energy intake
timeFrame: Day 1
measure: Meal energy intake
timeFrame: Day 2
Secondary outcomes:
measure: Hunger questionnaire
timeFrame: 0 and 60 min after the meal began
measure: Fullness questionnaire
timeFrame: 0 and 60 min after the meal began
measure: Desire to eat questionnaire
timeFrame: 0 and 60 min after the meal began
measure: Thirst questionnaire
timeFrame: 0 and 60 min after the meal began
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Texas Christian University
state: Texas
Study officials:
affiliation: Tzu Chi University
name: Meena Shah, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05957653: Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort
Official title: Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort After Robot-assisted Radical Prostatectomy: a Randomized, Double-blind, Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Prostate Cancer
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2023-07-24
Enrollment: 140
Sex: MALE
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy.

The main question it aims to answer is to evaluate incidence of CRBD immediately after extubation in resuscitation.

A total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. After drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out.

Then, the incidence of CRBD was compared between the two groups.


Eligibility criteria: Inclusion Criteria:

1. aged 18-79 years, ASA class I-II
2. participants undergoing robot-assisted radical prostatectomy under general anesthesia
3. signed informed consent and volunteered to participate in the experiment

Exclusion Criteria:

1. urethral stricture, difficulty in inserting catheter or urethral bleeding during catheterization
2. a preexisting bladder disease such as an overactive bladder, bladder outflow obstruction, and neurogenic bladder
3. cognitive impairment or communication disorders
4. severe heart, lung, liver, kidney and immune system diseases
5. confirmed or suspected allergy to this trial drug

Primary outcomes:
measure: incidence of CRBD
timeFrame: immediately after extubation in resuscitation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01458353: Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer
Official title: Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer: Are There Differences in the Peritoneal Contamination After Performing a Stapled or a Handsewn Anastomosis?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Peritoneal Contamination After Ileocolonic Anastomosis
Wound Infection
Intra-abdominal Abscess
Keywords: Right-sided colon cancer
Ileocolonic anastomosis
stapled anastomosis
handsewn anastomosis
peritoneal contamination
microbiological spectrum
Lead sponsor: Hospital General Universitario Elche
Sponsor class: OTHER
First posted: 2011-10-24
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Despite performing colonic surgery with strict asepsia measures, minimizing the contact of the colon lumen with the peritoneum, some contamination is nearly impossible to avoid. In stapled anastomosis, the hole opened in the colon is minimum, just the necessary for introducing the parts of the mechanical devices. In handsewn anastomosis, the colonic lumen is more exposed to the peritoneum, despite the colonic occlusion with clamps meanwhile the suture is performed.

Hypothesis: After stapled anastomoses, the peritoneal contamination should be lower than after handsewn ones.


Eligibility criteria: Inclusion Criteria:

* diagnosis of right-sided colon cancer and plans to undergo an elective surgery with curative aims.

Primary outcomes:
measure: Peritoneal contamination after finishing the ileocolonic anastomosis
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Elche
country: Spain
facility: Hospital General de Elche
state: Alicante
Study officials:
affiliation: Hospital General de Elche
name: Jaime Ruiz-Tovar, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital General de Elche
name: Antonio Arroyo, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Ruiz-Tovar J, Santos J, Arroyo A, Llavero C, Lopez A, Frangi A, Armananzas L, Alcaide MJ, Candela F, Calpena R. Microbiological spectrum of the intraperitoneal surface after elective right-sided colon cancer: are there differences in the peritoneal contamination after performing a stapled or a handsewn anastomosis? Int J Colorectal Dis. 2012 Nov;27(11):1515-9. doi: 10.1007/s00384-012-1492-9. Epub 2012 May 12.
Clinical trial NCT01310153: Effect of Supine or Prone Position After Caesarean Birth
Official title: Effect of Supine or Prone Position at Delivery on Respiratory Outcomes in Full-Term Infants Following Elective Caesarean Birth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Distress
Transient Tachypnea of the Newborn
Delayed Transition of the Newborn
Persistent Pulmonary Hypertension
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
First posted: 2011-03-08
Enrollment: 65
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Respiratory Distress is a frequent clinical diagnosis of babies delivered by elective Caesarean birth. There has been no study comparing the efficacy of immediately positioning a newly born infant prone vs. supine for the first 30 60 seconds of life after delivery by Caesarean birth.

Detailed description: This study hypothesizes that when the infant is prone they will have postural drainage, better dorsal lung expansion, less vagal response from suctioning and less agitation secondary to the righting reflex.

This study will compare 1033 term babies divided by randomization into two groups prone and supine. During the study, care givers will monitor and record incidence and severity of Respiratory Distress, Use of FiO2 or respiratory support, admissions to NICU.

Eligibility criteria: Inclusion Criteria:

\* Any woman not in labor who are undergoing elective Cesarean birth at term, 37 to 41 completed weeks gestation.

Exclusion Criteria:

* any woman with prior rupture of membranes
* diabetes mellitus, gestational diabetes,
* any woman receiving sedation
* using medication such as Demerol, magnesium sulfate or general anesthesia
* any woman who has a known drug history
* any known macrosomia
* known congenital anomalies or meconium stained fluid
* any woman with illnesses such as maternal fever, chorioamnionitis, severe neonatal distress
* any woman with compromised infant at delivery
* oligohydramnios
* history of antenatal steroids.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Jack D. Weiler Hospital of the Albert Einstein College of Medicine
state: New York
Study officials:
affiliation: Montefiore Medical Center
name: Orna Rosen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03468153: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Official title: The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Lymphoma
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
Collaborators: name: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
First posted: 2018-03-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with relapsed or refractory lymphoma often develop resistance to chemotherapy. Chimeric antigen receptor-modified T cell (CART) therapy showed promising effect in B-cell malignancies these years. CD19 and CD22 are proteins expressed on the surface of the lymphoma cells in patients with CD19+CD22+ lymphoma. The CAR enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22. This is a phase 2 trial to study the safety and efficacy of dual specificity CD19 and CD22 CAR-T cell immunotherapy for CD19+CD22+ relapsed and refractory lymphoma.


Eligibility criteria: Inclusion Criteria:

* Histological detection confirmed CD19/CD22 postive lymphoma;
* Recieved more than 2 lines of chemotherapy;
* Not eligible for hematopoietic stem cell transplantation or relapsed after hematopoietic stem cell transplantation;
* Life expectation for more than 3 months;
* ECOG ≥ 2;
* Adequate organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT \< 2 × upper limitation of normal; SpO2 \> 92%;
* CBC results: Hb ≥ 80g/L, ANC \> 1 × 10E9/L, Plt ≥ 50 × 10E9/L;
* Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion;
* With measurable disease;
* Written informed consent could be acquired;

Exclusion Criteria:

* Immunosuppressive agents or steroids in recent 1 week before recruitment;
* Uncontrolled infection;
* HIV positive ;
* Active HBV or HCV infection;
* Women in pregnancy and lactation;
* Refuse to conception control during treatment and 1 year after CAR-T infusion;
* Uncured malignancies other than non-Hodgkin lymphoma;
* Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma;
* Inheritated immune deficiancy;
* Severe heart disease.

Primary outcomes:
measure: Overall remission rate
timeFrame: 4 weeks after infusion
Secondary outcomes:
measure: Adverse toxicity
timeFrame: Day 0, day 4, week 1, week 3, week 4, month 2, month 12 after CAR-T cells were infused
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Ruijin Hospital
state: Shanghai
Study officials:
References: